Advisory Board April 1, 2024

There is a lot to be excited about in the new era of drugs, but there is a lot to be anxious about too, including high costs and impending legislation. Radio Advisory’s Rachel Woods sat down with Advisory Board experts Rachael Peroutky and Chloe Bakst to discuss how the industry should be thinking about this new era of drugs, and why healthcare organizations can’t afford to sit around today and strategize later.

Below is a summary of key takeaways from the interview. Download the Radio Advisory episode for the full conversation.

Ready-to-use slides: How to navigate the evolving high-cost drug landscape

Challenges and opportunities in the drug space

The drug space is experiencing significant changes, including the introduction of high-cost...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
23andMe: What If …
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
Pharmacies Should Adopt Proactive Health, Wellness to Help Patients

Share This Article